Fentanyl self-testing in a community-based sample of people who inject drugs, San Francisco.


Journal

The International journal on drug policy
ISSN: 1873-4758
Titre abrégé: Int J Drug Policy
Pays: Netherlands
ID NLM: 9014759

Informations de publication

Date de publication:
08 2020
Historique:
received: 16 02 2020
revised: 05 05 2020
accepted: 11 05 2020
pubmed: 10 6 2020
medline: 29 7 2021
entrez: 10 6 2020
Statut: ppublish

Résumé

Fentanyl test strips (FTS) can prevent overdose by identifying unknown fentanyl-laced drugs. We measured FTS use amongst people who inject drugs (PWID) in San Francisco. Data were from a cross-sectional survey of PWID in 2018, recruited by respondent-driven sampling. Participants were asked about FTS use in the last 12 months. Of 458 PWID surveyed, 45.4% had used an FTS in the last 12 months. FTS use was higher among PWID younger in age (adjusted odds ratio [AOR] 0.97 per year, 95% confidence interval [CI] 0.95-0.98), witnessing overdose (AOR 2.40, 95% CI 1.36-4.23), currently owning naloxone (AOR 2.92, 95% CI 1.76-4.87), and receiving overdose training (AOR 1.62, 95% CI 1.04-2.51). FTS use was lower among Black/African Americans (AOR 0.56, 95% CI 0.34-0.93). Amongst FTS users, 80.2% had a positive result, of whom 43.4% did not change their use of the drug, 26.5% abstained from using it, and 30.1% used a lower dose. Efforts to promote the use of FTS may have reached under half of PWID in San Francisco. Avenues need to be found to increase the role of FTS as a harm reduction approach to prevent overdose, particularly for older and Black/African American PWID.

Sections du résumé

BACKGROUND
Fentanyl test strips (FTS) can prevent overdose by identifying unknown fentanyl-laced drugs. We measured FTS use amongst people who inject drugs (PWID) in San Francisco.
METHODS
Data were from a cross-sectional survey of PWID in 2018, recruited by respondent-driven sampling. Participants were asked about FTS use in the last 12 months.
RESULTS
Of 458 PWID surveyed, 45.4% had used an FTS in the last 12 months. FTS use was higher among PWID younger in age (adjusted odds ratio [AOR] 0.97 per year, 95% confidence interval [CI] 0.95-0.98), witnessing overdose (AOR 2.40, 95% CI 1.36-4.23), currently owning naloxone (AOR 2.92, 95% CI 1.76-4.87), and receiving overdose training (AOR 1.62, 95% CI 1.04-2.51). FTS use was lower among Black/African Americans (AOR 0.56, 95% CI 0.34-0.93). Amongst FTS users, 80.2% had a positive result, of whom 43.4% did not change their use of the drug, 26.5% abstained from using it, and 30.1% used a lower dose.
CONCLUSION
Efforts to promote the use of FTS may have reached under half of PWID in San Francisco. Avenues need to be found to increase the role of FTS as a harm reduction approach to prevent overdose, particularly for older and Black/African American PWID.

Identifiants

pubmed: 32516685
pii: S0955-3959(20)30128-6
doi: 10.1016/j.drugpo.2020.102787
pii:
doi:

Substances chimiques

Pharmaceutical Preparations 0
Fentanyl UF599785JZ

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

102787

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None

Auteurs

Hayoung Oh (H)

School of Public Health, University of California, Berkeley, Berkeley, CA USA.

Kyu Kim (K)

College of Natural Resources, University of California, Berkeley, Berkeley, CA USA.

Desmond Miller (D)

Center for Public Health Research, San Francisco Department of Public Health, San Francisco, CA USA.

Danielle Veloso (D)

Center for Public Health Research, San Francisco Department of Public Health, San Francisco, CA USA.

Jessica Lin (J)

Center for Public Health Research, San Francisco Department of Public Health, San Francisco, CA USA.

Willi McFarland (W)

Center for Public Health Research, San Francisco Department of Public Health, San Francisco, CA USA. Electronic address: willi.mcfarland@sfdph.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH